Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cost of Revenue (2018 - 2025)

Historic Cost of Revenue for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Q3 2025 value amounting to $28.0 million.

  • Ultragenyx Pharmaceutical's Cost of Revenue rose 3315.73% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.5 million, marking a year-over-year increase of 3431.04%. This contributed to the annual value of $76.7 million for FY2024, which is 6971.84% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Cost of Revenue stood at $28.0 million, which was up 3315.73% from $23.0 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Cost of Revenue high stood at $28.7 million for Q1 2025, and its period low was $3.1 million during Q2 2021.
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Cost of Revenue value was $11.0 million (recorded in 2023), while the average stood at $12.9 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first plummeted by 3597.88% in 2021, then soared by 16371.17% in 2022.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Cost of Revenue stood at $3.5 million in 2021, then skyrocketed by 51.58% to $5.3 million in 2022, then skyrocketed by 126.57% to $12.1 million in 2023, then surged by 40.19% to $16.9 million in 2024, then surged by 65.69% to $28.0 million in 2025.
  • Its last three reported values are $28.0 million in Q3 2025, $23.0 million for Q2 2025, and $28.7 million during Q1 2025.